Y-Biologics, Inc. (KOSDAQ:338840)
13,550
+450 (3.44%)
At close: Jun 11, 2026
Y-Biologics Revenue
Y-Biologics had revenue of 281.89M KRW in the quarter ending March 31, 2026, a decrease of -30.77%. This brings the company's revenue in the last twelve months to 2.79B, down -44.55% year-over-year. In the year 2025, Y-Biologics had annual revenue of 2.91B, down -49.45%.
Revenue (ttm)
2.79B
Revenue Growth
-44.55%
P/S Ratio
76.17
Revenue / Employee
n/a
Employees
n/a
Market Cap
212.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.91B | -2.85B | -49.45% |
| Dec 31, 2024 | 5.76B | 2.28B | 65.64% |
| Dec 31, 2023 | 3.48B | -671.48M | -16.18% |
| Dec 31, 2022 | 4.15B | -696.78M | -14.37% |
| Dec 31, 2021 | 4.85B | -1.88B | -27.99% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| ISU Abxis | 58.94B |
| NIBEC | 32.34B |
| Genome & Company | 24.02B |
| Prestige Biologics | 18.03B |
| Bio Solution | 15.82B |
| TiumBio | 13.13B |
| Kangstem Biotech | 3.42B |
| curacle co.,ltd. | 1.06B |